Oxidative Stress News and Research

RSS

Oxidative Stress is a condition in which antioxidant levels are lower than normal. Antioxidant levels are usually measured in blood plasma.

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

12 Feb 2010

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

People with cystic fibrosis, an inherited disease that clogs airways with thick mucous, frequently have lung infections that defy treatment. While the life expectancy for children with cystic fibrosis has increased over the past few decades, many lives are still shortened in young adulthood by the ravages of lung infections.

10 Feb 2010

Eating strategies can reduce cell damage and enhance sports performance

For a week Ms Gravina evaluated players from the first two Athletic teams (Superleague and National League), in order to observe their eating habits and where they could improve.

19 Jan 2010

Study finds no elevated risk of dust-related disease for subway workers

New York subway commuters may worry more about rats and rising fares than dust floating through the system, but for the workers who spend their whole shift below ground, air quality has long been a concern. Results from a new pilot study using miniaturized air samplers to look at steel dust exposure may help them breathe easier.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

E-The Environmental Magazine: Environmental toxicity drives up autism rates

As many as one in 90 children are today being diagnosed with autism--and autism research continues to focus almost exclusively on genetics. In its January/February 2010 issue (posted now at: www.emagazine.com), E-The Environmental Magazine looks at another factor that may be driving up autism rates--environmental toxicity.

7 Jan 2010

LifeVantage receives formal approval to launch Protandim in Mexico

LifeVantage Corporation, the maker of science-based solutions to oxidative stress, announced today that the Company has received formal approval from the Mexican government to launch its flagship product, Protandim®, in Mexico. Initial shipments have cleared customs and Protandim® has been shipped to distributors in Mexico.

6 Jan 2010

LifeVantage announces Protandim human clinical trials for non-alcoholic steatohepatitis

LifeVantage Corporation, the maker of Protandim® and TrueScience(TM) Anti-Aging Cream, science-based solutions to oxidative stress, announced today that the Company's flagship product, Protandim, a patented dietary supplement composed of five highly synergistic "indirect antioxidants", is currently the subject of two human clinical trials at the University of Colorado, Denver.

5 Jan 2010

Vitamin C reverses accelerated aging due to Werner's syndrome

A new research discovery published in the January 2010 print issue of the FASEB Journal suggests that treatments for disorders that cause accelerated aging, particularly Werner's syndrome, might come straight from the family medicine chest. In the research report, a team of Canadian scientists show that vitamin C stops and even reverses accelerated aging in a mouse model of Werner's syndrome, but the discovery may also be applicable to other progeroid syndromes.

5 Jan 2010

Closer to the root cause of diabetes

A new research discovery published online in the FASEB Journal (http://www.fasebj.org) may change the perception and treatment of diabetes. That's because scientists have moved closer toward correcting the root cause of the disease rather than managing its symptoms. Specifically researchers identified a protein (G6PD protein) and its antioxidant product (NAPDH) that both prevent the death and promote the growth of cells which produce and release insulin in the pancreas (beta cells).

5 Jan 2010

CRN stands by Ginkgo biloba's effectiveness in improving cognitive function

"It is important to put this study into context and to remember that there is a large body of previously published evidence, which suggests that Ginkgo biloba may help improve cognitive impairment in older adults. There are also additional ongoing clinical trials, the results of which may address some of the limitations of the current study. The results of this single study add to the overall data on Ginkgo biloba, including valuable evidence in support of Ginkgo's safety profile, but should not be viewed as the final word.

30 Dec 2009

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

Discovery of beta cell defending enzyme raises hope for new treatments against diabetes

Cells in your body are constantly churning out poisonous forms of oxygen (oxidants) and mopping them up with a countervailing force of proteins and chemicals (anti-oxidants).

28 Dec 2009

Tips to achieve fitness and weight loss goals

More than 100 million Americans made New Year resolutions for 2009, and four out of five were not able to stick with them, according to the third annual Franklin Covey New Year’s Resolution survey released in January 2009.

23 Dec 2009

High prevalence of type 2 diabetes may be linked to excess niacin intake

Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.

23 Dec 2009

LifeVantage pays Zrii $400,000 to settle litigation

LifeVantage Corporation, the maker of Protandim® and TrueScience(TM) Anti-Aging Cream, science-based solutions to oxidative stress, announced today that the Company has entered into a settlement agreement with, among other parties, Zrii, LLC.

19 Dec 2009

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009

Scientists present new research on adipocyte regulation

The ninth Colloque Médecine et Recherche of la Fondation Ipsen devoted to Endocrinology, held in Paris on December 4, 2009, has reviewed the recent progress in understanding the regulation of fat storage in the body and the consequences of the breakdown of this regulation.

14 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Oxidative Stress News and Research

Further Reading

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

Eating strategies can reduce cell damage and enhance sports performance

Study finds no elevated risk of dust-related disease for subway workers

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

E-The Environmental Magazine: Environmental toxicity drives up autism rates

LifeVantage receives formal approval to launch Protandim in Mexico

LifeVantage announces Protandim human clinical trials for non-alcoholic steatohepatitis

Vitamin C reverses accelerated aging due to Werner's syndrome

Closer to the root cause of diabetes

CRN stands by Ginkgo biloba's effectiveness in improving cognitive function

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Discovery of beta cell defending enzyme raises hope for new treatments against diabetes

Tips to achieve fitness and weight loss goals

High prevalence of type 2 diabetes may be linked to excess niacin intake

LifeVantage pays Zrii $400,000 to settle litigation

Nitric oxide opens up new treatment option for septic shock

Scientists present new research on adipocyte regulation

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News